At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
In Brief
A Phase 2 clinical trial evaluating External Beam Radiation Therapy, Laboratory Biomarker Analysis, and 1 other intervention for Gastric Adenocarcinoma and 5 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Palliative radiation therapy, such as external beam radiation therapy, uses high energy beams to treat symptoms that are caused by tumors. Giving pembrolizumab together with palliative radiation therapy may work better in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
Study Details
Timeline
Interventions
Undergo palliative external beam radiation therapy
Correlative studies
Given IV